Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome)

NCT00510965 is registered in ClinicalTrials.gov with University Hospital, Bonn as lead sponsor.

NCT NCT00510965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00510965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ranibizumab in Choroidal Neovascularization (CNV) Due to Pseudoxanthoma Elasticum (PXE, Groenblad-Strandberg-Syndrome)
Lead sponsor
University Hospital, Bonn
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2007
Completion date
April 30, 2010
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

choroidal neovascularization